Retevmo (selpercatinib), Korea’s only selective RET inhibitor, has reportedly cleared price negotiations for national health insurance coverage, paving the way for potential reimbursement in October.

Retevmo (selpercatinib) - Eli Lilly

Sep 10, 2026